Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Capital Expenditures (2021 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Capital Expenditures for 5 consecutive years, with $40754.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 66.92% year-over-year to $40754.0, compared with a TTM value of $112682.0 through Dec 2025, up 4.84%, and an annual FY2025 reading of $81742.0, down 31.99% over the prior year.
  • Capital Expenditures was $40754.0 for Q4 2025 at Neuroone Medical Technologies, up from $10607.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $175694.0 in Q1 2023 and bottomed at $10607.0 in Q3 2025.
  • Average Capital Expenditures over 5 years is $54137.5, with a median of $37131.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures skyrocketed 222.54% in 2023, then plummeted 89.37% in 2024.
  • Year by year, Capital Expenditures stood at $61491.0 in 2021, then crashed by 81.28% to $11512.0 in 2022, then surged by 222.54% to $37131.0 in 2023, then tumbled by 34.24% to $24416.0 in 2024, then surged by 66.92% to $40754.0 in 2025.
  • Business Quant data shows Capital Expenditures for NMTC at $40754.0 in Q4 2025, $10607.0 in Q3 2025, and $24416.0 in Q4 2024.